Journal of Dermatological Treatment

BACKGROUND: Psoriasis is a complex, chronic, lifelong inflammatory skin disease characterized by the development of erythematous, indurated, scaly, pruritic and often painful skin plaques, and it is currently incurable. It profoundly affects psychological wellbeing and social functioning and has significant associated co-morbidities. To improve clinical approaches, understanding of the experiences of patients with psoriasis is needed. OBJECTIVE: To explore the experiences and coping behaviours of patients with psoriasis...

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare autoinflammatorydisorder without standardized therapy. IL-17 inhibitors have been effective in individual cases. However, some patients with SAPHO may develop psoriasiform or eczematous lesions as a paradoxical side of treatment with biologics. We describe a patient with both secukinumab-induced paradoxical skin lesions and primary SAPHO syndromefor whom tofacitinib treatment led to rapid remission. A 42-year-old man with SAPHO developed paradoxical eczematous lesionsafter 3 weeks of secukinumab treatment...

INTRODUCTION: Treatments for nonmelanoma skin cancer (NMSC) include excision (surgical removal) and destruction (cryotherapy or curettage with or without electrodesiccation) in addition to other methods. Although cure rates are similar between excision and destruction for low-risk NMSCs, excision is substantially more expensive. Performing destruction when appropriate can reduce costs while providing comparable cure rate and cosmesis. OBJECTIVE: To identify characteristics associated with exclusive (outlier) performance of excision or destruction for NMSC...

No abstract text is available yet for this article.

The treatment of moderate-to-severe atopic dermatitis (AD) in the elderly population could be challenging due to their comorbidities and side effects of conventional systemic drugs.

Patients who completed the originating studies, BREEZE-AD1 (NCT03334396), BREEZE-AD2 (NCT03334422), and BREEZE-AD7 (NCT03733301), were eligible for enrolment in the multicentre, phase 3, long-term extension study BREEZE-AD3 (NCT03334435). At week 52, responders and partial responders to baricitinib 4 mg were re-randomized (1:1) into the sub-study to dose continuation (4 mg, N = 84), or dose down-titration (2 mg, N = 84).Maintenance of response was assessed from week 52 to 104 of BREEZE-AD3...

Onychogryphosis is a form of nail deformity characterized by a distorted, yellowish-brown thickened nail plate that is skewed, grossly thickened, and partly curved like a ram's horn. Although onychogryphosis has been described for more than one hundred years, there is no curative treatment for onychogryphosis. Nonsurgical conservative procedures and nail avulsion with or without matricectomy are the common treatment procedures. The recurrence rate is high, so patients' needs are not met in many cases. Herein, we report for the first time the intramatrix injection of dexpanthenol in the treatment of onychogryphosis with excellent result...

Background Dose reduction (DR) of adalimumab, etanercept and ustekinumab has proven to be (cost-)effective in psoriasis patients with low disease activity. Further implementation is needed to establish application of DR for eligible patients. Objectives To evaluate implementation of protocolized biologic DR in daily practice. Methods A pilot implementation study was performed in 3 hospitals during 6 months. By combining education and protocol development, involved healthcare providers (HCPs) were directed towards adoption of protocolized DR...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

The overlap of psoriasis and atopic dermatitis (AD) is rare and treating moderate-to-severe cases can be challenging. Conventional immune-suppressive drugs cannot be used long-term, and no biological drugs are currently approved for treating both conditions.We report the cases of four patients with overlapping features of both psoriasis and AD. After being treated with several systemic drugs, including gold-standard treatments for both psoriasis and AD, they received upadacitinib 15 or 30 mg, achieving complete remission...

BACKGROUND AND OBJECTIVES: There has been no validated tool for objectively quantifying the overall condition and characteristics of the scalp. This study aimed to establish and validate a new classification and scoring system for evaluating scalp conditions. METHODS: The Scalp Photographic Index (SPI) using a trichoscope grades 5 features of scalp conditions (Dryness, Oiliness, Erythema, Folliculitis, and Dandruff) on a score of 0 to 3. To evaluate the validity of SPI, SPI grading was performed by 3 experts on the scalps of 100 subjects along with a dermatologist's assessment of the scalps and a scalp-related symptom survey...

BACKGROUND: Platelet-rich plasma (PRP) is an adjunctive treatment in androgenetic alopecia (AGA). Its role as a monotherapy, when compared to FDA-approved therapies in moderate grades of androgenetic alopecia is not established. OBJECTIVES: We sought to study the efficacy and safety of standardized non-activated PRP preparation against topical minoxidil in AGA. METHODS: Men aged 20-50 with Grade III and IV (Modified Hamilton-Norwood) AGA were randomized to receive 5% Minoxidil (x6 months) or PRP injections (monthly x3)...

No abstract text is available yet for this article.

BACKGROUND: Psoriasis is a chronic, immune-mediated, systemic inflammatory disorder associated with high costs. This study evaluated real-world treatment patterns and associated costs in patients in the United States with psoriasis initiating systemic oral or biologic treatments. METHODS: This retrospective cohort study used IBM® (now Merative™) MarketScan® Commercial and Medicare claims (January 1, 2006-December 31, 2019) to evaluate patterns of switching, discontinuation, and nonswitching in two cohorts of patients initiating oral or biologic systemic therapy...

No abstract text is available yet for this article.

BACKGROUND: Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately controlled with current therapies. METHODS: This post-hoc analysis examined associations between improvements in pruritus (visual analog scale [VAS]) and eczema (Eczema Area and Severity Index [EASI]), and achievement of other clinically relevant endpoints including the Insomnia Severity Index (ISI), Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM)...

OBJECTIVE: This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor. METHODS: This retrospective cohort study used Optum Clinformatics® Data Mart to identify propensity score-matched patients initiating apremilast, tumor necrosis factor inhibitors, or interleukin inhibitors, with 12-month baseline and 24-month follow-up data. Switch, discontinuation, persistence, healthcare resource utilization, and total healthcare costs were assessed...

BACKGROUND: Head-to-head comparisons through randomized controlled trials (RCTs) provide high-quality evidence to inform healthcare decisions. In their absence, indirect comparisons are often performed; however, evidence is limited on how valid matching-adjusted indirect comparison (MAIC)-based comparative efficacy estimates are vs. RCT-based estimates. OBJECTIVES: Compare MAIC and RCT results of guselkumab vs. secukinumab and ixekizumab to provide insight into validity of results generated using MAIC methods...

No abstract text is available yet for this article.